Showing 801 - 820 results of 115,466 for search '(( a non decrease ) OR ( 5 ((((step decrease) OR (teer decrease))) OR (a decrease)) ))', query time: 1.63s Refine Results
  1. 801

    Image2_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  2. 802

    Table2_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.DOCX by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  3. 803

    Image11_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  4. 804

    Image3_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  5. 805

    Image13_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  6. 806

    Image14_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  7. 807

    Image1_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF by Runzhi Huang (7428713)

    Published 2022
    “…External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings.</p><p>Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. …”
  8. 808
  9. 809
  10. 810

    Table2_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.docx by Peng Cao (107508)

    Published 2022
    “…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
  11. 811

    Table1_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.xlsx by Peng Cao (107508)

    Published 2022
    “…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
  12. 812

    Table1_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.xlsx by Peng Cao (107508)

    Published 2022
    “…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
  13. 813

    Table2_Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.docx by Peng Cao (107508)

    Published 2022
    “…Creatinine clearance (CrCl) was identified as a covariate to CL, and ERCC1 (rs3212986) and CYP3A5 (rs776746) gene polymorphisms as covariates to Q. …”
  14. 814
  15. 815
  16. 816

    Dose response association of objective physical activity with mental health in a representative national sample of adults: A cross-sectional study by Paquito Bernard (5892197)

    Published 2018
    “…For daily steps, inverted U-shaped curve suggested increasing benefits until a plateau between 5 000 and 16 000 steps. …”
  17. 817
  18. 818

    Effects of ROCK inhibitors H-1152 and Y-27632 on TNF-induced MLC phosphorylation, actin and CL5 reorganization and the fall in TEER. by Paul R. Clark (714064)

    Published 2015
    “…D) Effects of H-1152 and Y-27632 on the phase 1 and phase 2 TEER decreases induced by TNF. Starting at T<sub>0</sub>, HDMEC plated on ECIS 96-well arrays received a 1 hour pre-treatment with vehicle (top panel, n = 4, 4) or with a ROCK inhibitor, either H-1152 (at 1 or 10 μM, middle panel, n = 6, 6) or Y-27632 (at 1 or 10 μM, bottom panel, n = 6, 6). …”
  19. 819
  20. 820